A study by Janson et al. on the long-term management of CS comparing treatment with octreotide alone and in combination with IFN-α concluded that a combination of octreotide and IFN-α is most beneficial for patients since it demonstrated additive clinical effects without any severe toxicity. The gene discussed is IFNA1; the disease is Cowden syndrome 1.